The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis

PLoS Genetics

Volumn 7, Issue 12, 2011, Pages

  Tateno, Toru ^a,b   Asa, Sylvia L ^a,b   Zheng, Lei ^a,b   Mayr, Thomas ^c   Ullrich, Axel ^c   Ezzat, Shereen ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLYCINE; PROLACTIN; SERINE; STAT3 PROTEIN; DASATINIB; FGFR4 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GROWTH HORMONE; PYRIMIDINE DERIVATIVE; STAT3 PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ACROMEGALY; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; CONTROLLED STUDY; FGFR4 GENE; GENE ACTIVATION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HORMONAL CARCINOGENESIS; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; HYPOPHYSIS CELL; HYPOPHYSIS TUMOR; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE SRC; PROLACTIN SYNTHESIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME; ANIMAL; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCK-IN TECHNIQUES; GENES, SRC; GROWTH HORMONE; HUMANS; MICE; MITOCHONDRIA; PHOSPHORYLATION; PITUITARY NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLACTIN; PYRIMIDINES; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SERINE; STAT3 TRANSCRIPTION FACTOR; THIAZOLES;

EID: 84855290115     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002400     Document Type: Article

References (45)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, et al. (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101: 613-619.
2. Asa SL, Ezzat S, (2002) The pathogenesis of pituitary tumours. Nat Rev Cancer 2: 836-849.
3. Asa SL, Ezzat S, (2009) The pathogenesis of pituitary tumors. Annu Rev Pathol 4: 97-126.
4. Vallar L, Spada A, Giannattasio G, (1987) Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330: 566-568.
5. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, et al. (1989) GTPase inhibiting mutations activate the alpha-chain of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 340: 692-696.
6. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, et al. (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276: 404-407.
7. Zhuang Z, Ezzat S, Vortmeyer AO, Weil R, Oldfield EH, et al. (1997) Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 57: 5446-5451.
8. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, et al. (2007) Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92: 1891-1896.
9. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, et al. (2000) Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 26: 89-92.
10. Gejman R, Batista DL, Zhong Y, Zhou Y, Zhang X, et al. (2008) Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 93: 4119-4125.
11. Revill K, Dudley KJ, Clayton RN, McNicol AM, Farrell WE, (2009) Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma. Endocr Relat Cancer 16: 537-548.
12. Scully KM, Rosenfeld MG, (2002) Pituitary development: regulatory codes in mammalian organogenesis. Science 295: 2231-2235.
13. De Moerlooze L, Spencer-Dene B, Revest J, Hajihosseini M, Rosewell I, et al. (2000) An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Develop 127: 483-492.
14. Celli G, LaRochelle WJ, Mackem S, Sharp R, Merlino G, (1998) Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J 17: 1642-1655.
15. Ezzat S, Smyth HS, Ramyar L, Asa SL, (1995) Heterogeneous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. J Clin Endocrinol Metab 80: 878-884.
16. Abbass SAA, Asa SL, Ezzat S, (1997) Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab 82: 1160-1166.
17. Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL, (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109: 69-78.
18. Yu S, Asa SL, Weigel RJ, Ezzat S, (2003) Pituitary tumor AP-2alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4. J Biol Chem 278: 19597-19602.
19. Ezzat S, Yu S, Asa SL, (2003) Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5′ fibroblast growth factor receptor-4 promoter. Am J Pathol 163: 1177-1184.
20. Ezzat S, Zheng L, Asa SL, (2004) Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18: 2543-2552.
21. Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, et al. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62: 840-847.
22. Thussbas C, Nahrig J, Streit S, Bange J, Kriner M, et al. (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24: 3747-3755.
23. Wang J, Stockton DW, Ittmann M, (2004) The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 10: 6169-6178.
24. Morimoto Y, Ozaki T, Ouchida M, Umehara N, Ohata N, et al. (2003) Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer 98: 2245-2250.
25. Streit S, Bange J, Fichtner A, Ihrler S, Issing W, et al. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111: 213-217.
26. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, et al. (2000) Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 29: 3309-3320.
27. Reich NC, (2009) STAT3 revs up the powerhouse. Sci Signal 2: e61.
28. Seitzer N, Mayr T, Streit S, Ullrich A, (2010) A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 70: 802-812.
29. Asa SL, (2001) Transgenic and knockout mouse models clarify pituitary development, function and disease. Brain Pathol 11: 371-383.
30. Eswarakumar VP, Lax I, Schlessinger J, (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16: 139-149.
31. Takeda K, Akira S, (2000) STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11: 199-207.
32. Chung J, Uchida E, Grammer TC, Blenis J, (1997) STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 17: 6508-6516.
33. Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, et al. (2002) Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 16: 1394-1406.
34. Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, et al. (2002) Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and-independent mechanisms. J Clin Invest 110: 973-981.
35. Asa SL, DiGiovanni R, Jiang J, Ward ML, Loesch K, et al. (2007) A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Res 67: 7505-7511.
36. Ross RJ, (1999) The GH receptor and GH insensitivity. Growth Horm IGF Res 9 (Suppl B): 42-45.
37. Melmed S, Yamashita S, Yamasaki H, Fagin J, Namba H, et al. (1996) IGF-I receptor signalling: lessons from the somatotroph. Recent Prog Horm Res 51: 189-215.
38. Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, et al. (2004) Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24: 407-419.
39. Yu H, Jove R, (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105.
40. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, et al. (2009) Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324: 1713-1716.
41. Ezzat S, Zheng L, Winer D, Asa SL, (2006) Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. Mol Endocrinol 20: 2965-2975.
42. Lindauer M, Hochhaus A, (2010) Dasatinib. Recent Results Cancer Res 184: 83-102.
43. Kim LC, Song L, Haura EB, (2009) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6: 587-595.
44. Jenkins PJ, Bustin SA, (2004) Evidence for a link between IGF-I and cancer. Eur J Endocrinol 151 (Suppl 1): S17-S22.
45. Asa SL, (2011) Tumors of the Pituitary Gland. Armed Forces Institute of Pathology. Atlas of Tumor Pathology. Fourth Series, Fascicle 15. ARP Press, Washington, DC.